Status:
TERMINATED
An Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing Chemotherapy
Lead Sponsor:
AstraZeneca
Conditions:
Lung Cancer
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The main purpose of this study is the identification, description, and segmentation of non-small cell lung cancer (NSCLC) patients based on their value appraisal of treatment outcomes and all intermed...
Eligibility Criteria
Inclusion
- Patients suffering from non-small cell lung cancer (NSCLC) with clinical stage IIIB and IV tumours
- Patients with one chemotherapy regimen (first line treatment) (adjuvant chemotherapy following surgery is also regarded as first line treatment)
- Patients who are in transition from first to second line treatment
- Patients who signed an informed consent
Exclusion
- Chemotherapy naïve patients
- Patients ever enrolled in clinical studies treating non-small cell lung cancer (NSCLC) with chemotherapy (during 1st and 2nd line chemotherapy)
- Patients who ever had chemotherapy for an indication other than NSCLC
Key Trial Info
Start Date :
April 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2009
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00721981
Start Date
April 1 2009
End Date
October 1 2009
Last Update
December 10 2010
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Berlin, Germany
2
Research Site
Essen, Germany
3
Research Site
Heidelberg, Germany
4
Research Site
Hemer, Germany